Thyroid最新文献

{"title":"Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients.","authors":"Elias Chuki, Noha Behairy, Sungyoung Auh, Andrew Makarewicz, Chandra Nayan Uttarkar Vikram, Sonam Kumari, Padmasree Veeraraghavan, Craig Cochran, Sriram Gubbi, Joanna Klubo-Gwiezdzinska","doi":"10.1089/thy.2024.0588","DOIUrl":"10.1089/thy.2024.0588","url":null,"abstract":"<p><p><b><i>Background:</i></b> Familial non-medullary thyroid carcinoma (FNMTC) accounts for approximately 9% of differentiated thyroid cancer (DTC). There is conflicting data on the FNMTC aggressiveness compared with sporadic DTC (sDTC), leading to usually more extensive therapy applied for FNMTC, given its autosomal dominant genetic background. This study aimed to compare the progression-free survival (PFS) in patients with FNMTC and sDTC treated with standard therapy. <b><i>Methods:</i></b> This longitudinal retrospective cohort study included patients with FNMTC, defined as at least two first-degree relatives affected by DTC. FNMTC patients were matched with sDTC in a 1:3 ratio based on age, sex, American Thyroid Association recurrence risk stratification (ATA-R), extent of initial surgery, and diagnosis date. The primary outcome was PFS. Kaplan-Meier curves were used to compare PFS between the groups, and the Cox proportional hazards model was used to assess confounders. <b><i>Results:</i></b> From 95 affected FNMTC patients, 30 were excluded due to lack of follow-up data. The study population consisted of 65 FNMTC and 170 sDTC patients, with a median follow-up of 4.73 (2.87-10.27) years for FNMTC and 5.83 (2.33-10.79) years for sDTC (<i>p</i> = 0.76). There was 100% matching for ATA-R, sex, surgery type, and year of surgery and a satisfactory matching for age (43.12 ± 15.11 vs. 42.76 ± 12.46 years, <i>p</i> = 0.85). FNMTC exhibited a smaller tumor size (1.20 ± 0.96 vs. 1.89 ± 1.51 cm, <i>p</i> < 0.01) and fewer positive lymph nodes (range 0-13 vs. 0-38, <i>p</i> = 0.009) at presentation. The rate of repeated neck surgeries for persistent/recurrent disease was comparable between the groups: 13.8% (9/65) for FNMTC vs. 17.7% (30/170) for sDTC (<i>p</i> = 0.48). There was no difference in radioactive iodine (RAI) therapy dosage between the groups (104 [100-149] vs. 106 [76-160] mCi<i>, p =</i> 0.82). During follow-up, 15.4% of FNMTC and 18.2% of sDTC patients experienced disease progression (<i>p</i> = 0.61). PFS was non-different between groups (<i>p</i> = 0.56) and was associated with ATA-R (high vs. low hazard ratio [HR]: 9.2, confidence interval [CI]: 2.67-31.85, <i>p</i> < 0.001) and sex (male vs. female, HR: 2.5, CI: 1.11-5.6, <i>p</i> = 0.026). <b><i>Conclusions:</i></b> No difference in PFS between FNMTC and sDTC patients suggests comparable responsiveness to standard therapy. Therefore, the management of FNMTC should align with the standard of care for DTC to avoid overtreatment of FNMTC.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"642-651"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional Differences in the Management of Thyroid Eye Disease: Results from an International Clinical Practice Survey of Endocrinologists.","authors":"Danilo Villagelin, David S Cooper, Henry B Burch","doi":"10.1089/thy.2024.0759","DOIUrl":"10.1089/thy.2024.0759","url":null,"abstract":"<p><p><b><i>Background:</i></b> Over the past several decades, there have been indications of potential shifts in the diagnostic strategies and treatment of patients with Graves' disease (GD) and thyroid eye disease (TED). The objective of this study was to evaluate current practices in managing GD when complicated by moderate-to-severe TED worldwide. <b><i>Methods:</i></b> We recently reported results from a global online survey of endocrinologists comparing the management of GD in different scenarios. The current analysis focuses on regional differences in the diagnosis and treatment of GD when complicated by TED. <b><i>Results:</i></b> A total of 1252 respondents from 85 countries completed the survey. Regarding the initial diagnostic and treatment measures, there were no differences among the various geographical regions. Regarding the treatment of moderate-to-severe TED, the use of sodium selenite was higher in Europe (66.5%) and Oceania (60%) compared to other regions (<i>p</i> < 0.001). North American respondents were more likely to recommend teprotumumab and less likely to use glucocorticoids (<i>p</i> < 0.001). When comparing the treatment options for GD in patients with TED, although prolonged use of antithyroid drugs (ATD) remained the first choice in all regions, respondents from Europe, North America, and Oceania were more likely to recommend thyroidectomy than those from other regions (<i>p</i> < 0.001). Ophthalmologists, rather than endocrinologists, would more often be responsible for prescribing advanced medical therapy for TED in North America, Oceania, and Africa, while endocrinologists would have primary responsibility in other regions of the globe. <b><i>Conclusions:</i></b> Although there are regional differences, respondents generally employ the recommended diagnostic tools, treatments, and a multidisciplinary approach suggested by current clinical practice guidelines. However, there were examples of deviations from current guidance from professional societies.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"676-683"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144161108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Extraocular Muscle Enlargement in Graves' Orbitopathy and Acromegaly.","authors":"Chris Zajner, Nikhil Patil, Rachel McInnis, Stan Van Uum, Alexander Fraser, Pavlo Ohorodnyk, Lulu L C D Bursztyn","doi":"10.1089/thy.2024.0438","DOIUrl":"10.1089/thy.2024.0438","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> Extraocular muscle (EOM) enlargement occurs in both acromegaly and Graves' disease, but the degree and pattern of enlargement have not been directly compared in these patient groups. This study investigated whether acromegaly and Graves' orbitopathy (GO) are associated with different patterns of EOM enlargement at the time of diagnosis. <b><i>Study Design:</i></b> Retrospective cohort. <b><i>Methods:</i></b> All new patients with a diagnosis of acromegaly or GO who presented to St Joseph's Health Care in London, Ontario, between January 1, 2015, and July 1, 2020, and who underwent computed tomography (CT) scanning with adequate orbital imaging were considered for inclusion. We included age- and sex-matched control patients with pituitary macroadenomas without thyroid or growth hormone abnormalities. Orbital CT scans were analyzed by a single neuroradiologist, who measured the maximum diameter and cross-sectional area of each EOM. The relative likelihood of involvement of each rectus EOM was analyzed separately using an analysis of variance test. <b><i>Results:</i></b> We included 16 patients with GO, 17 with acromegaly, and 18 controls. Ages (mean ± standard deviation) of groups were 55.6 ± 18.0, 50.2 ± 15.7, and 49.3 ± 14.0 years. The mean maximum diameter of EOMs in GO, acromegaly, and controls was inferior rectus (IR) = 4.77 ± 1.53, 4.66 ± 0.61, and 3.68 ± 0.61 mm; medial rectus (MR) = 5.35 ± 2.23, 4.84 ± 0.81, and 3.65 ± 0.42 mm; superior rectus (SR) = 4.94 ± 1.84, 4.88 ± 0.91, and 3.68 ± 0.61 mm; and lateral rectus (LR) = 3.91 ± 1.59, 4.55 ± 0.60, and 3.20 ± 0.43 mm. The IR, MR, and SR muscles were significantly larger in the GO group compared with controls (IR, <i>p</i> = 0.020; SR, <i>p</i> = 0.004; MR, <i>p</i> < 0.001; and LR, <i>p</i> = 0.166), and all four EOMs were larger in acromegaly compared with controls (IR, <i>p</i> = 0.039; SR, <i>p</i> = 0.006; MR, <i>p</i> = 0.006; and LR, <i>p</i> = 0.001). There was no significant difference between the GO and acromegaly groups (IR, <i>p</i> = 0.959; SR, <i>p</i> = 0.987; MR, <i>p</i> = 0.408; and LR, <i>p</i> = 0.250). <b><i>Conclusions:</i></b> GO and acromegaly groups demonstrated the enlargement of the IR, MR, and SR muscles when compared with controls. The GO group did not show significantly larger EOM sizes compared with the acromegaly group. In the GO group, the IR, MR, and SR were similarly affected and did not follow previously described patterns of enlargement in GO.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"706-710"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Considerations in the Diagnosis and Management of Thyroid Dysfunction in Older Adults.","authors":"Sina Jasim, Maria Papaleontiou","doi":"10.1089/thy.2025.0128","DOIUrl":"10.1089/thy.2025.0128","url":null,"abstract":"<p><p><b><i>Background:</i></b> Thyroid dysfunction is common in older adults and poses diagnostic and management challenges for clinicians. In this narrative review, we present published data focusing on special considerations in the diagnosis and management of hypothyroidism and hyperthyroidism in older adults. <b><i>Methods:</i></b> A comprehensive literature search of the PubMed and Ovid MEDLINE databases was conducted from January 2000 to December 2024 to identify pertinent articles in English for this narrative review. <b><i>Results:</i></b> Due to significant cardiovascular risk if untreated, both overt hypothyroidism and hyperthyroidism should be treated in older adults. Findings from observational studies do not support treating older adults with subclinical hypothyroidism with a thyrotropin (TSH) <7 mIU/L. However, observational data have demonstrated an increased risk of cardiovascular mortality and stroke in older adults with subclinical hypothyroidism with TSH 7.0-9.9 mIU/L and of coronary heart disease, cardiovascular mortality, and heart failure in those with TSH ≥10 mIU/L, suggesting levothyroxine treatment in these individuals should be considered. Data from clinical trials failed to show improvement with levothyroxine in hypothyroidism symptoms or fatigue in older adults with subclinical hypothyroidism compared with placebo. Over- and under-replacement with thyroid hormone is common and should be avoided, as population-based studies have shown associations with adverse cardiovascular and skeletal events. Subclinical hyperthyroidism with a TSH <0.1 mIU/L should be treated in older individuals as it has been associated with increased cardiovascular risk and bone density loss based on observational data. Randomized controlled trials have shown that long-term low-dose methimazole is a viable alternative to radioactive iodine in older adults with hyperthyroidism. <b><i>Conclusions:</i></b> A personalized approach should be undertaken in the diagnosis and management of thyroid dysfunction in older adults. Multiple factors should be considered, including physiological age-related changes in thyroid function, comorbidities, and polypharmacy. Care should be taken to maintain euthyroidism in order to avoid adverse events.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"624-632"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12241845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valerie Anne Galton PhD: A Rosalind Pitt Rivers Protege by Pure Luck!","authors":"Terry F Davies","doi":"10.1089/thy.2025.0020","DOIUrl":"10.1089/thy.2025.0020","url":null,"abstract":"","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"599-606"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Natural Course of Low-Risk Papillary Thyroid Microcarcinoma During Pregnancy: A Prospective Active Surveillance Study.","authors":"Wen Liu, Zhizhong Dong, Weihan Cao, Haifei Jin, Yuting Li, Ping Lei, Xuejing Yan, Ruochuan Cheng","doi":"10.1089/thy.2024.0702","DOIUrl":"10.1089/thy.2024.0702","url":null,"abstract":"<p><p><b><i>Background:</i></b> Active surveillance (AS) has emerged as an established management strategy for patients with low-risk papillary thyroid microcarcinoma (PTMC). However, prior studies have suggested accelerated tumor growth during pregnancy, which raises concerns about the suitability of AS for reproductive-age patients. This study evaluates the longitudinal impact of pregnancy on tumor dynamics and validates the safety of AS management in this population. <b><i>Methods:</i></b> From February 2020 to October 2024, a single-institution prospective AS cohort enrolled 260 female patients diagnosed with low-risk PTMC. Eighteen female patients (21 pregnancy events) with complete series of ultrasound documentation underwent longitudinal analysis of changes in tumor size and growth velocity, with time-stratified comparisons before pregnancy, during pregnancy, and after delivery. Tumor doubling rate (TDR) was calculated to quantify tumor growth or shrinkage patterns across these periods. An increase in tumor size of 3 mm or more was defined as substantial enlargement. <b><i>Results:</i></b> Over a median follow-up of 59.0 (interquartile range 38.5, 72.0) months, tumor enlargement (>3 mm) was observed in 19.0% (4/21) of the PTMC cases by the last follow-up. During pregnancy, 76.2% (16/21) of tumors exhibited accelerated growth (TDR >0.5/year) or moderate growth (TDR 0.1-0.5/year), whereas postpartum stabilization (TDR -0.1 to 0.1/year) or regression (TDR <-0.1/year) occurred in 71.4% (15/21). The TDR peaked during pregnancy and decreased after delivery (0.39/year vs. -0.01/year, <i>p</i> = 0.006). Delayed surgery was required in only two patients and no instances of expanded surgical scope, T-stage progression, or tumor recurrence were observed. <b><i>Conclusion:</i></b> While pregnancy may transiently accelerate tumor growth in low-risk PTMC, most gestational changes are self-limited, with stabilization or regression commonly observed postpartum. AS remains a safe and effective strategy for reproductive-age patients, balancing oncologic safety with fertility preservation. Confirmatory studies incorporating extended follow-up and advanced imaging modalities are essential to further validate these findings and optimize clinical frameworks.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"684-690"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Report of SPECC1L::ALK Fusion in Medullary Thyroid Carcinoma with Remarkable Response to Alectinib.","authors":"Hervé Bischoff, Antonin Fattori, Fabien Moinard-Butot, Olivier Schneegans, Pablo Diaz, Damien Reita, Valérie Rimelen, Anne-Claire Voegeli, Laura Bender","doi":"10.1089/thy.2025.0017","DOIUrl":"10.1089/thy.2025.0017","url":null,"abstract":"<p><p><b><i>Background:</i></b> Rearrangements of the <i>ALK</i> gene are rare in medullary thyroid carcinoma (MTC), with limited data on the efficacy of ALK inhibitors in this context. Novel fusions, such as SPECC1L::ALK, have not been extensively studied. <b><i>Methods:</i></b> We present a case of a 33-year-old woman with metastatic MTC, in whom molecular profiling using next-generation sequencing (Archer FusionPlex®) identified a SPECC1L::ALK gene fusion. Treatment with the ALK inhibitor alectinib was initiated at 600 mg twice daily. <b><i>Results:</i></b> The patient demonstrated a dramatic partial to near-complete response after 6 days of treatment, as shown by positron emission tomography-computed tomography. At 6 weeks, a complete response was confirmed. Treatment was generally well tolerated, aside from grade 3 myalgia with elevated creatine phosphokinase, managed with temporary cessation and dose adjustment. As of the latest follow-up (8 months), the patient remains on alectinib with sustained complete response. <b><i>Conclusions:</i></b> This is the first report of a SPECC1L::ALK fusion in MTC. The dramatic response to alectinib highlights the importance of molecular profiling and suggests that ALK inhibitors may benefit patients with rare <i>ALK</i> fusions in thyroid cancers.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"701-705"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic and Functional Cross Talk Between the Thyroid and Liver.","authors":"Chiaw-Ling Chng, George Boon Bee Goh, Paul Michael Yen","doi":"10.1089/thy.2025.0178","DOIUrl":"10.1089/thy.2025.0178","url":null,"abstract":"<p><p><b><i>Background:</i></b> The liver and thyroid have complicated effects on each other's functions and metabolic homeostasis in the body. Both hypo- and hyperthyroidism influence hepatic carbohydrate and fat metabolism to regulate circulating glucose, cholesterol, and triglyceride levels. Hypothyroidism and \"intrahepatic\" hypothyroidism also contribute to the development of hypercholesterolemia and metabolic dysfunction-associated steatotic liver disease (MASLD). Likewise, hepatic dysfunction can modulate thyroid function by reducing thyroid hormone (TH) concentrations and their effects on peripheral tissues. <b><i>Summary:</i></b> In this review, we examine the impact of thyroid disorders and their treatment on hepatic physiology, metabolism, and pathology, as well as the influence of liver disease on thyroid function. We also describe the clinical and experimental evidence for THs playing significant roles in metabolic conditions such as metabolic syndrome, hyperlipidemia, and MASLD. Additionally, we summarize the current literature on the use of thyromimetics for the treatment of metabolic diseases. <b><i>Conclusions:</i></b> Recognizing the effects of the thyroid and THs on hepatic metabolism and fuel utilization, and the liver's role in modulating systemic TH action, is important for optimal clinical management of patients with thyroid and/or liver diseases. New emerging concepts on TH actions in the liver and the efficacy of thyromimetics for the treatment of MASLD have reshaped our understanding of the thyroid-liver relationship and the roles of THs in the pathogenesis and treatment of metabolic diseases.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"607-623"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reproductive Concern, Fertility Intention, and Pregnancy Outcomes in Young Women with Thyroid Cancer after Thyroid Surgery: A Prospective Cohort Study.","authors":"Fenghua Lai, Wanna Chen, Jiayuan Zhang, Wenxin Chen, Wenke Chen, Yuanyuan Zheng, Yuting Hong, Yufei He, Xuyang Li, Yu Yang, Tianyi Xu, Yingtong Hou, Xinwen Chen, Jianyan Long, Bin Li, Bo Lin, Sui Peng, Rebecca Bahn, Haixia Guan, Weiming Lv, Yihao Liu","doi":"10.1089/thy.2024.0660","DOIUrl":"10.1089/thy.2024.0660","url":null,"abstract":"<p><p><b><i>Background:</i></b> Factors contributing to the development of reproductive concern, fertility intention and pregnancy outcomes in young women following thyroidectomy are unclear. This study aimed to compare the reproductive concern, fertility intentions and pregnancy outcomes between young women who had either thyroid cancer (TC) or benign thyroid disease and were treated with total thyroidectomy (TT) or thyroid lobectomy (TL). <b><i>Methods:</i></b> This prospective cohort study enrolled women aged 20-40 and scheduled for thyroid surgery at a tertiary hospital in China from November 2019 to October 2021 (ChiCTR1900027205). Reproductive concern and intention were evaluated preoperatively and at 1, 3, 6, 12, 18, and 24 months postoperatively using Reproductive Concerns After Cancer (RCAC) and Fertility Intention Scale (FIS), respectively. Pregnancy outcomes were monitored. <b><i>Results:</i></b> Of the 482 eligible women, 402 women had TC (157 [39.1%] underwent TT), and 80 had benign thyroid disease (10 [12.5%] underwent TT). Compared with the benign group, the TC group had significantly higher RCAC scores from 3 months to 2 years postoperatively (all <i>p</i> < 0.05). The TC group had significantly lower postoperative FIS scores from 3 to 12 months after surgery than the benign group (all <i>p</i> < 0.05). Women with TC in the TT group had significantly higher RCAC scores than TL group at time points from 1 months to 2 years postoperatively, and had significantly lower postoperative FIS scores from 1 to 18 months after surgery (all <i>p</i> < 0.05). During the 2-year follow-up, 78 women became pregnant and 13 (16.7%) suffered pregnancy loss. No significant differences in adverse pregnancy outcomes were found between the TC group and benign thyroid disease group, or those between the TT group and the TL group of women with TC. Women with planned pregnancy and preconception counseling had significantly lower rates of pregnancy loss than those with unplanned pregnancy and no preconception counseling (4.0% vs. 22.6% and 11.7% vs. 33.3%, both <i>p</i> < 0.05). <b><i>Conclusions:</i></b> It is important to address reproductive concern and fertility intention postoperatively in young women with TC. Preconception counseling and planned pregnancy may be associated with a reduced risk of pregnancy loss after thyroid surgery.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"691-700"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long Noncoding RNAs Papillary Thyroid Carcinoma Susceptibility Candidate 3 Antisense 1 and Papillary Thyroid Carcinoma Susceptibility Candidate 3 Synergistically Regulate ZC3H12A mRNA Stability via Vimentin at 14q13.3 Thyroid Cancer Locus.","authors":"Yutong Zhang, Xiuzhi Shi, Shengqi Cheng, Jing Liu, Jianyun Shi, Zhekun An, Jiali Yao, Binbin Zou, Ming Gao, Xiaolong Cheng, Yanqiang Wang","doi":"10.1089/thy.2024.0674","DOIUrl":"10.1089/thy.2024.0674","url":null,"abstract":"<p><p><b><i>Background:</i></b> The 14q13.3 has been identified as a genetic locus associated with a genetically increased risk of papillary thyroid cancer (PTC) in several cohorts, yet its underlying regulatory mechanisms remain poorly understood. <b><i>Methods:</i></b> The full-length sequence of expressed sequence tag fragment AA632637 in the thyroid was obtained by rapid amplification of complementary DNA ends assay. Quantitative Reverse Transcription PCR (qRT-PCR) assays were utilized to examine the expression levels of the long noncoding RNA (lncRNA) in clinical thyroid tissues and cell lines. Functional assays, including cell proliferation, migration, invasion, and apoptosis assays, were conducted both <i>in vitro</i> and <i>in vivo</i>. Furthermore, RNA-seq analysis, actinomycin D assay, RNA pull-down, RNA immunoprecipitation, and dual-luciferase reporter assays were performed to identify the long noncoding RNA (lncRNA) binding targets and reveal the underlying regulatory mechanism. <b><i>Results:</i></b> We identified a previously unannotated lncRNA gene, named papillary thyroid carcinoma susceptibility candidate 3 antisense 1 (<i>PTCSC3-AS1</i>), within 14q13.3. The expression of <i>PTCSC3-AS1</i> was strongly downregulated in PTC tumor tissues, and restoration of <i>PTCSC3-AS1</i> expression in PTC cells inhibited tumorigenesis and promoted cell apoptosis. Moreover, <i>PTCSC3-AS1</i> and <i>PTCSC3</i>, two lncRNAs located on the opposite strands at 14q13.3, were revealed to synergistically interact with their shared binding protein vimentin. Forced overexpression of <i>PTCSC3</i> and <i>PTCSC3-AS1</i> revealed that <i>ZC3H12A</i>, a gene validated as a PTC suppressor, was the shared downstream target of the two lncRNAs. Vimentin significantly reduced the mRNA stability of <i>ZC3H12A</i>, while the upregulation of <i>PTCSC3</i> and <i>PTCSC3-AS1</i> suppressed the mRNA degradation of <i>ZC3H12A</i>. In addition, rs944289 and rs116909374 were identified as two potential causative variants with distinct regulatory roles in the 14q13.3 locus. Mechanistically, <i>PTCSC3-AS1</i> and <i>PTCSC3</i> protected <i>ZC3H12A</i> from vimentin-mediated mRNA degradation by targeting the <i>ZC3H12A</i> 3' untranslated region (3'UTR) during PTC initiation and progression. <b><i>Conclusion:</i></b> Our results suggest a novel dual-lncRNA regulatory model in the 14q13.3 risk locus and provide a comprehensive annotation of the <i>PTCSC3-AS1</i>/<i>PTCSC3</i>-vimentin-<i>ZC3H12A</i> signaling network in PTC genetic predisposition.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"662-675"},"PeriodicalIF":5.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}